Pertzye is the first and only pancreatic enzyme replacement therapy (PERT) with an FDA approved gastrostomy tube (G-tube) route of administration.
G-tube administration should only be performed with the contents of the 4,000 USP lipase units capsule. Pertzye 4,000 lipase units capsule contents may be given through a gastrostomy tube that is size 14 French or larger. Do not give Pertzye through a gastrostomy tube smaller than size 14 French. Click here or below to learn more.
PERTZYE is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement. Exercise caution when doses of PERTZYE exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
To avoid irritation of oral mucosa, do not chew PERTZYE or retain in the mouth.
Hyperuricemia may develop. Consider monitoring uric acid levels in patients with hyperuricemia, gout, or renal impairment.
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
There is theoretical risk of viral transmission with all pancreatic enzyme products including PERTZYE.
The most common adverse reactions (≥ 10%) are: diarrhea, dyspepsia, and cough.